Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports.
Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports.
复制标题
DOI：
10.1002/hep4.1959
复制
发表时间：
2022-08
影响因子：
5.1
通讯作者：
Lucena, M. Isabel
中科院分区：
文献类型：
--
作者：
Bjornsson, Einar S.;Medina-Caliz, Inmaculada;Andrade, Raul J.;Lucena, M. Isabel
呋喃妥因、米诺环素、甲基多巴和英夫利昔单抗已被发现可诱导自身免疫性肝炎（DI-AILH）。其他药物和草药和膳食补充剂（HDS）的证据尚不清楚。该研究的目的是建立标准，以定义和审查已发表的疑似DI-AILH的证据。在Pubmed中使用检索词“药物诱导的肝损伤”、“自身免疫性肝炎”和“药物诱导的自身免疫性肝炎”进行检索。DI-AILH定义为（1）药物作为肝损伤的潜在触发因素，具有与AIH一致的自身免疫特征和组织学结果;（2）停药后肝功能检查无恢复或不完全恢复或恶化;（3）需要皮质类固醇或自发恢复;（4）随访时无免疫抑制（IS），且IS停药后至少6个月未复发AIH;（5）可能诱发慢性AILH的药物。符合前四项标准的病例被认为是可能的DI-AILH，有三个可能的DI-AILH。常规药物（n = 148;女性79%;潜伏期2.6个月）和HDS（n = 38;女性50%）共确定了186份病例报告。最常报告的DI-AILH药物为干扰素（n = 37）、他汀类药物（n = 24）、甲泼尼龙（MPS）（n = 16）、阿达木单抗（n = 10）、伊马替尼（n = 8）和双氯芬酸（n = 7）。青牛胆和卡塔叶是唯一可能发生DI-AILH病例的HDS。在干扰素、伊马替尼、双氯芬酸和甲基强的松龙治疗后停止IS时，未观察到AIH复发。结论：除了公认的呋喃妥因、甲基多巴、肼苯哒嗪、米诺环素和英夫利昔单抗是DI-AILH的原因外，干扰素、伊马替尼、阿达木单抗和MPS是导致可能的DI-AILH的最佳记录药物。卡塔叶和心叶青牛胆是发现能够诱导DI-AILH的唯一HDS。由于这些药物，DI-AILH患者似乎很少需要长期免疫抑制。虽然一些药物有充分的证据证明能够诱导自身免疫性疾病，但许多其他药物和草药和膳食补充剂（HDS）的证据尚未分析。建立药物性肝炎（DI-AIH）标准，以分析疑似DI-AILH的病例报告。只有干扰素、伊马替尼、阿达木单抗、甲泼尼龙、阿拉伯茶和心叶青牛胆符合可能的DI-AILH标准。
Nitrofurantoin, minocycline, methyldopa and infliximab, have been found to induce autoimmune‐like hepatitis (DI‐AILH). Evidence for other drugs and herbal and dietary supplements (HDS) is unclear. The aims of the study were to establish criteria to define and review the published evidence of suspected DI‐AILH. Search was undertaken in Pubmed using search terms “drug‐induced liver injury,” “autoimmune hepatitis,” and “drug‐induced autoimmune hepatitis.” DI‐AILH was defined as (1) drug as a potential trigger of liver injury with autoimmune features and histological findings compatible with AIH; (2) no or incomplete recovery or worsening of liver tests after discontinuation of the drug; (3) corticosteroids requirement or spontaneous recovery; (4) follow‐up without immunosuppression (IS) and no relapse of AIH at least 6 months after discontinuation of IS; and (5) drugs potentially inducing AILH with a chronic course. Cases fulfilling the first four criteria were considered probable DI‐AILH with three possible DI‐AILH. A total of 186 case reports were identified for conventional drugs (n = 148; females 79%; latency 2.6 months) and HDS (n = 38; females 50%). The most commonly reported agents of DI‐AILH were interferons (n = 37), statins (n = 24), methylprednisolone (MPS) (n = 16), adalimumab (n = 10), imatinib (n = 8), and diclofenac (n = 7). Tinospora cordifolia and Khat were the only HDS with probable DI‐AILH cases. No relapses of AIH were observed when IS was stopped after interferons, imatinib, diclofenac, and methylprednisolone. Conclusion: Beyond well‐recognized nitrofurantoin, methyldopa, hydralazine, minocycline, and infliximab as causes of DI‐AILH, interferons, imatinib, adalimumab, and MPS were the best‐documented agents leading to probable DI‐AILH. Khat and Tinospora cordifolia were the only HDS found to be able to induce DI‐AILH. Long‐term immunosuppression appears to be rarely required in patients with DI‐AILH due to these drugs. Although some drugs have well‐documented ability to induce autoimmune‐like disorder, documented evidence for many other drugs and herbal and dietary supplements (HDS) has not been analyzed. Criteria for drug‐induced hepatitis (DI‐AIH) were set up to analyze case reports of suspected Di‐AILH. Only interferon, imatinib, adalimumab, methylprednisolone, and khat and Tinospora cordifolia were found to fulfill criteria for probable DI‐AILH.
登录
查看更多内容
影响因子：
25.7
作者：
Lohse, Ansgar W.;Chazouilleres, Olivier;Lenzi, Marco
通讯作者：
Lenzi, Marco
影响因子：
13.5
作者：
Mack, Cara L.;Adams, David;Czaja, Albert J.
通讯作者：
Czaja, Albert J.
DOI：
10.1016/j.cgh.2016.05.043
发表时间：
2017-01
期刊：
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子：
--
作者：
de Boer YS;Kosinski AS;Urban TJ;Zhao Z;Long N;Chalasani N;Kleiner DE;Hoofnagle JH;Drug-Induced Liver Injury Network
通讯作者：
Drug-Induced Liver Injury Network
影响因子：
0.8
作者：
Guzman G;Kallwitz ER;Wojewoda C;Chennuri R;Berkes J;Layden TJ;Cotler SJ
通讯作者：
Cotler SJ
DOI：
10.1097/00008571-199706000-00002
发表时间：
1997-06-01
期刊：
PHARMACOGENETICS
影响因子：
--
作者：
Belloc, C;Gauffre, A;Beaune, PH
通讯作者：
Beaune, PH